*NURSING > ESSAY > NR-293 Week 6 Assignment: RUA: Medication Teaching Plan – Nurtec (ODT) (All)

Also available in bundle ( Click Here )

NR-293 Week 6 Assignment: RUA: Medication Teaching Plan – Nurtec (ODT)

Document Content and Description Below

MEDICATION TEACHING PLAN 1 Medication Teaching Plan Chamberlain College of Nursing NR 293: Pharmacology for Nursing Practice Medication Teaching Plan Our names ar... e Jaime Weisel and Nnamdi Omeludike. Our project is covering the oral opioid antagonist medication known as Symproic. It is now December, 2018 and we are both stu- dents of Professor Gloria King-Hoff in the class ‘Pharmacology for Nursing Practice’, of the No- vember session. As stated before, Symproic is an opioid antagonist medication which is typically prescribed to patients currently experiencing Opioid Induced Constipation. According to the ‘Journal for Managed Care and Formulary Management’, “Opioid-induced constipation (OIC), new or worsening constipation occurring when initiating, changing, or increasing opioid use, represents the most common of these GI effects”(P.601). Due to this fact, our intended audience for this teaching would be patients diagnosed with chronic pain(which could be related to various illness) that are prescribed opioid analgesics to treat that pain, mainly adults as research for chil- dren and administration for children has not been done, nor has it been released. The goal of the brochure is to creatively inform our audience of the complications associated with opioid use as well as educating them on some of the adverse effects of opioids causing our audience the need to use our drug of choice Symproic. The brochure will also provide a detailed intervention on how Symproic can counter/lower some of these adverse effects, and again educating the our au- dience on the therapeutic effects, with the prescribed use of Symprioc, on the body. According to ‘Naldemedine: First Global Approval’, Symprioc “was associated with signiﬁcantly greater im- provements from baseline in the frequency of bowel movements per week compared with placebo (n = 620) at all assessed time points (weeks 12, 24, 36 and 52)” (Markham P.925) References Constipation too? Ready to make a move? (n.d.). Retrieved from https://www.symproic.com/ Hu, K., & Bridgeman, M. B. (2018). Naldemedine (Symproic) for the Treatment Of Opioid-In- duced Constipation. P&T: A Peer-Reviewed Journal for Managed Care & Formulary Man- agement, 43(10), 601–627.. Kaufman, M. B. (2017). Pharmaceutical Approval Update. P&T: A Peer-Reviewed Journal for Managed Care & Formulary Management, 42(8), 502–504. Retrieved from https://cham- berlainuniversity.idm.oclc.org/login?url=https://search.ebscohost.com/login.aspx?di- rect=true&db=ccm&AN=124448428&site=eds-live&scope=site New Drug Approvals. (2017). P&T: A Peer-Reviewed Journal for Managed Care & Formulary Management, 42(5), 296–297. Retrieved from https://chamberlainuniversity.idm.o- clc.org/login?url=https://search.ebscohost.com/login.aspx? direct=true&db=ccm&AN=122620653&site=eds-live&scope=site Markham, A. (2017). Naldemedine: First global approval. Drugs, 77(8), 923-927. doi:http://dx.doi.org.chamberlainuniversity.idm.oclc.org Symproic (Naldemedine Tablets): Side Effects, Interactions, Warning, Dosage & Uses. (n.d.). Re- trieved from https://www.rxlist.com/symproic-drug.htm [Show More]

Last updated: 2 years ago

Preview 1 out of 3 pages

Buy Now

Instant download

We Accept: